Floatz logo

SLC391

Lung Cancer Stage IV

SignalChem Lifesciences CorporationSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

67 Active assets in the Lung Cancer Stage IV cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
OTL-38
On Target Laboratories, LLC
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Carboplatin
SystImmune Inc.
Phase 3B
Nivolumab
M.D. Anderson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

SLC391 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
48 / 100
View asset →
neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →